Cleantech

Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing

Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from its Small Cap Growth Virtual Investor Conference held on December 1 st are now available for online viewing.

REGISTER NOW AT : https://bit.ly/3H26Z7H

The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download
investor materials from the company's resource section.

Select companies are accepting 1x1 management meeting requests through December 6 th .

December 1 st

Presentation Ticker(s)
Aquafil S.P.A. OTCQX: ECNLF | Euronext Star Milan: ECNL
AAC Clyde Space OTCQX: ACCMF | NASDAQ STOCKHOLM: AAC
Active Energy Group Plc OTCQB: ATGVF | AIM: AEG
Gamelancer Media Corp. OTCQB: GAMGF | CSE: GMNG
Saturn Oil + Gas Inc. OTCQX: OILSF | TSXV: SOIL
Good Natured Products Inc. OTCQX: GDNPF | TSXV: GDNP
Novonix Ltd. OTCQX: NVNXF | ASX: NVX
Alkaline Fuel Cell Power Corp. OTCQB: ALKFF | NEO: PWWR
Bigg Digital Assets Inc. OTCQX: BBKCF | CSE: BIGG
Solar Alliance Energy Inc. OTCQB: SAENF | TSXV: SOLR
Alvopetro Energy Ltd. OTCQX: ALVOF | TSXV: ALV
Black Swan Graphene Inc. OTCQB: BSWGF | TSXV: SWAN
VERSES Technologies Inc. OTCQX: VRSSF | NEO: VERS
ARway Corporation Pink: ARWYF | CSE: ARWY

To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com .

About Virtual Investor Conferences ®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

Media Contact:
OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com

Virtual Investor Conferences Contact:
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

PWWR:AQL
Alkaline Fuel Cell Power Logo

Alkaline Fuel Cell Power


Keep reading...Show less
Alkaline Fuel Cell Power Corp. Announces AGM Results

Alkaline Fuel Cell Power Corp. Announces AGM Results

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) ("AFCP" or the "Company") a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce the results of voting at its annual general meeting (" AGM ") of shareholders which was held on January 25, 2023 in person in Vancouver, British Columbia and by conference call (the " Meeting "). There were 19 shareholders represented in person or by proxy at the Meeting holding 2,423,369 common shares, representing 1.39% of the Company's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting is set out below:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Alkaline Fuel Cell Power Announces Resignation of Director

Alkaline Fuel Cell Power Announces Resignation of Director

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) ("AFCP" or the "Company") a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, announces the resignation of Joel Dumaresq as director, effective January 12, 2023. Mr. Dumaresq will remain as the Chief Financial Officer of the Company while the Company seeks a suitable replacement.

ABOUT Alkaline Fuel Cell Power CORP.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Alkaline Fuel Cell Power Corp. Announces Grant of Restricted Share Units

Alkaline Fuel Cell Power Corp. Announces Grant of Restricted Share Units

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) (" AFCP " or the " Company "), a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce that the Company has granted an aggregate of 9,541,557 restricted share units (" RSUs ") to certain arm's-length consultants of the Company (each, a " Consultant ").

The RSUs will vest in accordance with the terms of each Consultant's RSU agreement and in accordance with the Company's 2021 RSU Plan. Upon vesting, each RSU entitles the holder thereof to receive one common share in the capital of the Company.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
REPEAT - Alkaline Fuel Cell Power Corp. Announces Prototype Launch of Jupiter 1.0, a Powerful Fuel Cell System for Homes and Small Buildings, and Management Update

REPEAT - Alkaline Fuel Cell Power Corp. Announces Prototype Launch of Jupiter 1.0, a Powerful Fuel Cell System for Homes and Small Buildings, and Management Update

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) (" PWWR " or the " Company "), a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce that its wholly owned Belgium subsidiary, Fuel Cell Power NV (" FCP NV "), has launched the prototype of its micro-combined heat and power (" CHP ") fuel cell, named Jupiter 1.0 .

"Alkaline Fuel Cell Power is proud to present the prototype of our fuel cell system for homes and small buildings - Jupiter 1.0," stated Frank Carnevale, Chief Executive Officer of PWWR. "The Jupiter 1.0 prototype will be piloted with select strategic partners to demonstrate the advantages of delivering green hydrogen to homes and small buildings, globally. We thank staff for their dedication and effort to complete this important milestone on time."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Alkaline Fuel Cell Power Corp. Announces Prototype Launch of Jupiter 1.0, a Powerful Fuel Cell System for Homes and Small Buildings, and Management Update

Alkaline Fuel Cell Power Corp. Announces Prototype Launch of Jupiter 1.0, a Powerful Fuel Cell System for Homes and Small Buildings, and Management Update

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) (" PWWR " or the " Company "), a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce that its wholly owned Belgium subsidiary, Fuel Cell Power NV (" FCP NV "), has launched the prototype of its micro-combined heat and power (" CHP ") fuel cell, named Jupiter 1.0 .

"Alkaline Fuel Cell Power is proud to present the prototype of our fuel cell system for homes and small buildings - Jupiter 1.0," stated Frank Carnevale, Chief Executive Officer of PWWR. "The Jupiter 1.0 prototype will be piloted with select strategic partners to demonstrate the advantages of delivering green hydrogen to homes and small buildings, globally. We thank staff for their dedication and effort to complete this important milestone on time."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BriaCell CEO Letter to Shareholders

BriaCell CEO Letter to Shareholders

  • Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization.
  • Successful completion of the pivotal study could be followed by a Biologics License Application submission and commercialization.
  • Pivotal study's primary endpoint to be linked to survival improvement.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today issues a letter to shareholders from Dr. William V. Williams, BriaCell's President and CEO.

Dear BriaCell Shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BriaCell to Investigate Alleged Illegal Trading of Public Securities

BriaCell to Investigate Alleged Illegal Trading of Public Securities

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announced today that it has approved measures to address alleged illegal trading activity of its publicly traded securities. The Company believes that certain individuals andor companies may have engaged in manipulative andor suspected illegal trading practices that may have artificially depressed its share price. As a result, BriaCell is implementing a plan to address this issue which may include legal action.

BriaCell is working to build one of the leading immuno-oncology companies in the biotech sector with a singular focus on commercializing our novel immunotherapy approach for cancer patients. While our clinical team remains dedicated to developing these desperately needed therapies, the Company recognizes that recent milestones have been achieved with the support of loyal investors who are instrumental in the ongoing development of our assets. By taking action to protect the interests of our shareholders, we are also protecting the interests of the Company and the tens of thousands of cancer patients in need of effective treatment options. To this end, BriaCell is pursuing avenues to address alleged illegal activities carried out by various parties potentially working collusively with the intent of depressing the Company's share price while undermining the interest of our shareholders.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Nano One Provides Progress Update on the Successful Integration of Candiac LFP Operation

Nano One Provides Progress Update on the Successful Integration of Candiac LFP Operation

Highlights

  • One-Pot trials commencing and decommissioning of unused equipment progressing.
  • Functional re-org implemented to align innovation and commercialization centres.
  • Completed integration of Candiac team and facility, focus now on post-merger activities.
  • Focusing on meeting market demand while harnessing government support.

nano one® Materials Corp. ("nano one" or the "Company"), a clean technology company focused on the production of cathode materials used in lithium-ion batteries, is pleased to provide an update on the reorganization of the combined teams, and the transformation of the Candiac lithium iron phosphate ("LFP") facility to the One-Pot process, following completion of the acquisition previously announced on November 1, 2022

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT Combination in Advanced Metastatic Breast Cancer

BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT Combination in Advanced Metastatic Breast Cancer

  • BriaCell has received agreement and positive feedback from its End of Phase II meeting with the FDA for lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor, in advanced metastatic breast cancer.
  • After reviewing BriaCell's Fast Track designated Phase I / IIa data, the FDA has agreed on the primary end point, the essential elements of the pivotal registration study design, and type of patients to be included.
  • Registration study success could lead to a Biologics License Application (BLA) submission and commercialization approvals for BriaCell's novel immunotherapy approach.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that it has received agreement and positive feedback from its End of Phase II meeting with the FDA regarding BriaCell's lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor (under Fast Track designation), in advanced metastatic breast cancer.

BriaCell and the FDA have agreed on the primary end point, the essential elements of the study design, and the type of patients to be enrolled in BriaCell's upcoming pivotal clinical study. This pivotal registration study will be enrolling advanced metastatic breast cancer patients for whom no approved treatment options exist.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Cypher Announces Cancellation of Stock Options

Cypher Announces Cancellation of Stock Options

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Cypher Metaverse Inc. ("Cypher'' or the "Company") (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) announced today that it has cancelled a total of 1,287,500 stock options, including 377,500 to insiders as they were no longer serving their purpose in aligning the interest of the holders with those of shareholders

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
BriaCell Announces New Patent Issuance, Bria-OTS IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment

BriaCell Announces New Patent Issuance, Bria-OTS IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment

  • BriaCell's new patent protects its novel personalized off-the-shelf cell-based technology for breast cancer and multiple other cancer indications until 2040.
  • BriaCell expects to initiate its Bria-OTS™ clinical study under an Investigational New Drug Application (IND) in the first half of 2023, in accordance with FDA guidance.
  • Two additional clinical sites are now active in Phase II Bria-IMT™ study to broaden patient access: Carle Cancer Institute in Urbana, Illinois and the American Oncology Network, LLC (AON) in Baltimore, Maryland.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that it has received an Issue Notification from the United States Patent and Trademark Office for the composition of matter and method of use of its personalized off-the-shelf cell-based immunotherapy for cancer. The patent will issue on January 24, 2023 as US Patent No. 11,559,574 with the term extending to May 25, 2040. Additionally, BriaCell was awarded an Australian patent (Patent No. 2017224232, extends to February 27, 2037) covering composition of matter and method of use for its whole-cell cancer immunotherapy technology in Australia.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×